Immune checkpoint inhibitors in older adults
Abstract
Cancer is primarily a disease of older adults. The treatment of advanced stage tumors usually involves the use of systemic agents that may be associated with significant risk of toxicity, especially in older patients. Immune checkpoint inhibitors are newcomers to the oncology world with improved efficacy and better safety profiles when compared to traditional cytotoxic drugs. This makes them an attractive treatment option. While there are no elderly specific trials, this review attempts to look at the current available data from a geriatric oncology perspective. We reviewed data from phase III studies that led to newly approved indications of checkpoint inhibitors in non-small cell lung cancer, melanoma, and renal cell cancer. Data were reviewed with respect to response, survival, and toxicity according to three groups: <65 years, 65-75 years, and >75 years. Current literature does not allow one to draw definitive conclusions regarding the role of immune checkpoint inhibitors in older adults. However, they may offer a potentially less toxic but equally efficacious treatment option for the senior adult oncology patient.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Immunosenescence influences the efficacy of immune checkpoint inhibitors in older people.
“In fact, immunosenescence influences the efficacy of the immune checkpoint inhibitors in older people (169);”
From Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019) · cites this paper as [169]
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,314 · see citing works
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · see citing works
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781 · see citing works
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676 · see citing works
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178 · see citing works
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072 · see citing works
Cohen, H. T., & McGovern, F. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043172 · Cited by 1,575 · see citing works
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415 · see citing works
Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.688 · Cited by 1,387 · see citing works
Fossella, F. V., DeVore, R. F., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L. A., Miller, V. A., Lee, J. S., Moore, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2354 · Cited by 1,360 · see citing works
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
Lewis, J. H., Kilgore, M. L., Goldman, D. P., Trimble, E. L., Kaplan, R. S., Montello, M. J., Housman, M. G., & Escarce, J. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.010 · Cited by 1,029 · see citing works
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Walker, L. S. K., & Sansom, D. M. (2011) · Nature reviews. Immunology · doi:10.1038/nri3108 · Cited by 786 · see citing works
Toxicities of Immunotherapy for the Practitioner
Weber, J. S., Yang, J. C., Atkins, M. B., & Disis, M. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0379 · Cited by 652 · see citing works
Nagele, E. P., Han, M., Acharya, N. K., DeMarshall, C., Kosciuk, M. C., & Nagele, R. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060726 · Cited by 309 · see citing works
Tsaknaridis, L., Spencer, L., Culbertson, N. E., Hicks, K., LaTocha, D. H., Chou, Y. K., Whitham, R. H., Bakke, A. C., Jones, R. E., Offner, H., et al. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10766 · Cited by 197 · see citing works
Pawelec, G., Derhovanessian, E., & Larbi, A. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.06.012 · Cited by 175 · see citing works
Kwak, E. L., LoRusso, P. M., Hamid, O., Jankú, F., Kittaneh, M., Catenacci, D. V. T., Chan, E. W., Bekaii‐Saab, T., Amore, B. M., Hwang, Y. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.3_suppl.1 · Cited by 109 · see citing works
SHEPHERD, F. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90297-0 · Cited by 66 · see citing works
Hodi, F. S., Postow, M. A., Chesney, J. A., Pavlick, A. C., Robert, C., Grossmann, K. F., McDermott, D. F., Linette, G. P., Meyer, N., Giguere, J. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9004 · Cited by 44 · see citing works
Hammers, H. J., Plimack, E. R., Sternberg, C. N., McDermott, D. F., Larkin, J., Ravaud, A., Rini, B. I., Sharma, P., Bhagavatheeswaran, P., Gagnier, P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps4578 · Cited by 42 · see citing works
Sparano, J. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.7890 · Cited by 26 · see citing works
Horn, L., Brahmer, J. R., Reck, M., Borghaei, H., Spigel, D. R., Steins, M. B., Ready, N., Chow, L. Q. M., Vokes, E. E., Felip, E., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv532.01 · Cited by 13 · see citing works
Gettinger, S. N., Horn, L., Ramalingam, S. S., Spigel, D. R., Paz-Ares, L. G., Paik, P. K., Reck, M., Reckamp, K. L., Mazières, J., Stinchcombe, T. E., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)31735-x · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Aiello, A., Farzaneh, F., Candore, G., Caruso, C., Davinelli, S., Gambino, C. M., Ligotti, M. E., Zareian, N., & Accardi, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02247 · Cited by 693 · see citing works
The aging lung: Physiology, disease, and immunity
Schneider, J. L., Rowe, J. H., Garcia-de-Alba, C., Kim, C. F., Sharpe, A. H., & Haigis, M. C. (2021) · Cell · doi:10.1016/j.cell.2021.03.005 · Cited by 500 · see citing works
Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology
Garcovich, S., Colloca, G. A., Sollena, P., Bellieni, A., Balducci, L., Cho, W. C. S., Bernabei, R., & Peris, K. (2017) · Aging and Disease · doi:10.14336/ad.2017.0503 · Cited by 252 · see citing works
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
Elias, R., Giobbie-Hurder, A., McCleary, N. J., Ott, P., Hodi, F. S., & Rahma, O. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0336-8 · Cited by 218 · see citing works
Huang, X.-Z., Gao, P., Song, Y.-X., Xu, Y., Sun, J.-X., Chen, X.-W., Zhao, J.-H., & Wang, Z.-N. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1665973 · Cited by 132 · see citing works
“Immune checkpoint inhibitors (ICIs) that target programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), have altered the therapeutic landscape and have become an attractive treatment strategy in several malignancies due to their high efficacy an…”
BackgroundImmunotherapy comes of age: Immune aging & checkpoint inhibitors
Elias, R., Karantanos, T., Sira, E., & Hartshorn, K. L. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.02.001 · Cited by 133 · see citing works
van Holstein, Y., Kapiteijn, E., Bastiaannet, E., van den Bos, F., Portielje, J. E. A., & de Glas, N. A. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00697-2 · Cited by 114 · see citing works
O’Connor, J. M., Fessele, K. L., Steiner, J., Seidl-Rathkopf, K., Carson, K. R., Nussbaum, N. C., Yin, E. S., Adelson, K. B., Presley, C. J., Chiang, A. C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0798 · Cited by 113 · see citing works
Aging, immune senescence, and immunotherapy: a comprehensive review
Elias, R., Hartshorn, K., Rahma, O., Lin, N., & Snyder-Cappione, J. E. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.08.006 · Cited by 96 · see citing works
Hong, H., Wang, Q., Li, J., Liu, H. B., Meng, X., & Zhang, H. (2019) · Journal of Cancer · doi:10.7150/jca.30723 · Cited by 89 · see citing works
O’Reilly, A., Hughes, P., Mann, J. K., Lai, Z. M., Teh, J. J., McLean, E., Edmonds, K., Lingard, K., Chauhan, D., Lynch, J., et al. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-04818-w · Cited by 71 · see citing works
Saba, N. F., Blumenschein, G. R., Guigay, J., Licitra, L. F., Fayette, J., Harrington, K. J., Kiyota, N., Gillison, M. L., Ferris, R. L., Jayaprakash, V., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.06.017 · Cited by 68 · see citing works
Frailty and checkpoint inhibitor toxicity in older patients with melanoma
Bruijnen, C. P., Koldenhof, J. J., Verheijden, R. J., van den Bos, F., Emmelot‐Vonk, M. H., Witteveen, P. O., & Suijkerbuijk, K. P. M. (2022) · Cancer · doi:10.1002/cncr.34230 · Cited by 45 · see citing works
The aging lung: microenvironment, mechanisms, and diseases
Wang, Y., Huang, X., Luo, G., Xu, Y., Deng, X., Lin, Y., Wang, Z., Zhou, S., Wang, S., Chen, H., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1383503 · Cited by 46 · see citing works
Gardner, J. K., Mamotte, C. D. S., Jackaman, C., & Nelson, D. J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.07.002 · Cited by 40 · see citing works
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer
Genova, C., Rossi, G., Rijavec, E., Biello, F., Barletta, G., Tagliamento, M., & Grossi, F. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1313228 · Cited by 36 · see citing works
Efficacy of Immune Checkpoint Inhibitors and Age in Cancer Patients
Huang, X., Gao, P., Song, Y., Sun, J., Chen, X., Zhao, J., & Wang, Z. (2020) · Immunotherapy · doi:10.2217/imt-2019-0124 · Cited by 36 · see citing works
Bastiaannet, E., Battisti, N. M. L., Loh, K. P., de Glas, N. A., Soto‐Pérez‐de‐Celis, E., Baldini, C., Kapiteijn, E., & Lichtman, S. M. (2018) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2018.06.009 · Cited by 31 · see citing works
Rutherford, S. C., Li, H., Herrera, A. F., LeBlanc, M. L., Ahmed, S., Davison, K. L., Parsons, S. K., Unger, J. M., Perry, A. M., Casulo, C., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00204 · Cited by 30 · see citing works
Checkpoint inhibition and melanoma: Considerations in treating the older adult
Friedman, C. F., & Wolchok, J. D. (2017) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2017.04.003 · Cited by 30 · see citing works
Zhang, L., Sun, L., Yu, J., Shan, F., Zhang, K., Pang, X., Ma, C., Zhang, Y., Shen, M., Ma, S., et al. (2019) · BioMed Research International · doi:10.1155/2019/9853701 · Cited by 30 · see citing works
Effect of age and sex on immune checkpoint expression and kinetics in human T cells
Reitsema, R. D., Cadena, R. H., Nijhof, S., Abdulahad, W. H., Huitema, M. G., Paap, D., Brouwer, E., Boots, A. M. H., & Heeringa, P. (2020) · Immunity & Ageing · doi:10.1186/s12979-020-00203-y · Cited by 28 · see citing works
Immunotherapy in Older Adults with Cancer
Godby, R. C., Johnson, D. B., & Williams, G. R. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0806-2 · Cited by 26 · see citing works
Liu, W., Huo, G., & Chen, P. (2023) · BMC Cancer · doi:10.1186/s12885-023-10959-3 · Cited by 25 · see citing works
Toxicity in Older Patients with Cancer Receiving Immunotherapy: An Observational Study
Hoi, E. T. V., Trompet, S., van Holstein, Y., van den Bos, F., van Heemst, D., Codrington, H., Labots, G., Lohman, S., Özkan, A., Portielje, J. E. A., et al. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01114-z · Cited by 24 · see citing works
RANKL treatment restores thymic function and improves T cell–mediated immune responses in aged mice
Santamaria, J. C., Chevallier, J., Dutour, L., Picart, A., Kergaravat, C., Cieślak, A., Amrane, M., Vincentelli, R., Puthier, D., Clave, E., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adp3171 · Cited by 24 · see citing works
Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults
Elias, R., Morales, J. K., & Presley, C. J. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0619-0 · Cited by 22 · see citing works
Sakakida, T., Ishikawa, T., Uchino, J., Tabuchi, Y., Komori, S., Asai, J., Arai, A., Tsunezuka, H., Kosuga, T., Konishi, H., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11875 · Cited by 21 · see citing works
Sussman, T. A., Knackstedt, R. W., Wei, W., Funchain, P., & Gastman, B. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004994 · Cited by 19 · see citing works
Cybulska-Stopa, B., Lugowska, I. A., Jagodzińska-Mucha, P., Koseła-Paterczyk, H., Kozak, K., Klimczak, A., Świtaj, T., Ziobro, M., Roman, A., Rajczykowski, M., et al. (2019) · Advances in Dermatology and Allergology · doi:10.5114/ada.2018.79940 · Cited by 19 · see citing works
Araji, G., Maamari, J., Ahmad, F. A., Zareef, R. O., Chaftari, P. S., & Yeung, S. J. (2021) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-21-10 · Cited by 18 · see citing works
Management of Skin Cancer in the Elderly
Renzi, M. A., Schimmel, J., Decker, A., & Lawrence, N. (2019) · Dermatologic Clinics · doi:10.1016/j.det.2019.02.003 · Cited by 17 · see citing works
Zheng, S., Cui, H., Duan, H., Peng, Y., Li, Q., Sun, C., Zhang, J., Shen, W., Zhang, X., Tan, K., et al. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02241-5 · Cited by 17 · see citing works
Pradeep, J., Win, T. T., Aye, S. N., & Sreeramareddy, C. T. (2022) · Journal of Cancer · doi:10.7150/jca.72210 · Cited by 16 · see citing works
Immunotherapy in Older Patients with Cancer: A Narrative Review
Smith, A., Boby, J. M., Benny, S. J., Ghazali, N., Vermeulen, E. T., & George, M. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s435001 · Cited by 15 · see citing works
Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database
Conic, R. R. Z., Knackstedt, R. W., Sussman, T. A., Rambhia, S., Damiani, G. B., Funchain, P., Ko, J. S., & Gastman, B. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000672 · Cited by 12 · see citing works
Nivolumab in Metastatic Melanoma: Good Efficacy and Tolerability in Elderly Patients
Luca, R. D., Meraviglia, S., Blasi, L., Maiorana, A., & Cicero, G. (2020) · Current Oncology · doi:10.3747/co.27.5293 · Cited by 12 · see citing works
IL-1 and senescence: Friends and foe of EGFR neutralization and immunotherapy
Romaniello, D., Gelfo, V., Pagano, F., Sgarzi, M., Morselli, A., Girone, C., Filippini, D. M., D’Uva, G., & Lauriola, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1083743 · Cited by 11 · see citing works
Real‑world challenge for clinicians treating advanced gastroesophageal adenocarcinoma (Review)
Baxter, M. A., Petty, R., Swinson, D., Hall, P. S., & O’Hanlon, S. (2021) · International Journal of Oncology · doi:10.3892/ijo.2021.5202 · Cited by 10 · see citing works
Li, J., Zhang, X., Zhou, S., Zhou, Y., & Liu, X. (2023) · Cancer Medicine · doi:10.1002/cam4.5669 · Cited by 7 · see citing works
Immune signatures predicting responses to immunomodulatory antibody therapy
Pawelec, G. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.003 · Cited by 6 · see citing works
Immune checkpoint inhibitors in older patients with cancer
Arora, S., & Kumar, L. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_126_21 · Cited by 6 · see citing works
Wang, D. Y., Gilbert, J., & Kim, Y. J. (2017) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2017.04.006 · Cited by 5 · see citing works
Predicting treatment toxicity in older adults with cancer
Menjak, I. B., Mata, D. G. D. M. M., Chesney, T. R., & Haase, K. R. (2021) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000539 · Cited by 4 · see citing works
Impact of geriatric impairments on outcomes of single‐agent immunotherapy in solid tumors
Özkan, A., de Joode, K., Kapiteijn, E., Slingerland, M., Zunder, S. M., van den Bos, F., Mooijaart, S. P., den Boogaard, A. U., Trompet, S., Westgeest, H. M., et al. (2025) · International Journal of Cancer · doi:10.1002/ijc.70185 · Cited by 3 · see citing works
Utilization and survival benefit of adjuvant immunotherapy in resected high-risk stage II melanoma
Wong, W. G., Holguin, R. A. P., Stahl, K. A., Olecki, E. J., Pameijer, C., & Shen, C. (2022) · Surgery in Practice and Science · doi:10.1016/j.sipas.2022.100056 · Cited by 3 · see citing works
Comorbidity and Polypharmacy in Older Adults with Cancer and Frailty
Berger, A. S., Pearce, M. S., de Matos, L. V., & Alibhai, S. M. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-89162-6_6 · Cited by 3 · see citing works
Neue Entwicklungen in der geriatrischen Onkologie
Goede, V. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-122556 · Cited by 3 · see citing works
Narrative review of immunotherapy and radiation therapy in elderly patients
Chau, B., LaGuardia, J. S., Hui, C., Ye, L., Xing, Y., Massarelli, E., & Amini, A. (2021) · Translational Cancer Research · doi:10.21037/tcr-20-2637 · Cited by 3 · see citing works
Toxicities in Immune Checkpoint Inhibitors
Lee, S. S., Loecher, M., & Puzanov, I. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54948-6.00011-1 · Cited by 2 · see citing works
Reiman, L. T., Walker, Z. J., Babcock, L. R., Forsberg, P. A., Mark, T. M., & Sherbenou, D. W. (2021) · Aging and Cancer · doi:10.1002/aac2.12022 · Cited by 1 · see citing works
Zytostatika-assoziierte Toxizitäten in der geriatrischen Onkologie
Schulze‐Bergkamen, H. (2018) · Springer eBooks · doi:10.1007/978-3-662-48727-3_6
Das Hodgkin-Lymphom beim alten und geriatrischen Patienten
Böll, B. (2018) · Springer eBooks · doi:10.1007/978-3-662-48727-3_22
Zuo, H., Chen, L., Li, N., & Song, Q. (2020) · doi:10.21203/rs.2.24382/v1
Beal, J. R., Schvartsman, G., Munhoz, R. R., Karnakis, T., & Kaliks, R. A. (2021) · Brazilian Journal of Oncology · doi:10.5935/2526-8732.20210015
Das Hodgkin-Lymphom beim alten und geriatrischen Patienten
Böll, B. (2017) · Springer eBooks · doi:10.1007/978-3-662-49083-9_22-1
Zytostatika-assoziierte Toxizitäten in der geriatrischen Onkologie
Schulze‐Bergkamen, H. (2016) · Springer eBooks · doi:10.1007/978-3-662-49083-9_6-1
Önder, A. H., & Çatlı, M. M. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105108
Reitsema, R. D., Hid Cadena, R., Nijhof, S., Abdulahad, W. H., Huitema, M. G., Paap, D., Brouwer, E., Boots, A. M. H., & Heeringa, P. (2020) · Figshare · doi:10.6084/m9.figshare.13192507
- Authors
- Elias, R., Morales, J., Rehman, Y., & Khurshid, H.
- Affiliations
- Boston University (US)
- Virginia Commonwealth University (US)
- Rhode Island Hospital (US)
- Corresponding author
- Elias, Rawad
- Venue
- Current Oncology Reports
- Published
- 2016-06-10
- Volume
- 18
- Issue
- 8
- Pages
- 47-47
- ISSN
- 1523-3790 (ISSN-L)
- 1534-6269
- OpenAlex
- W2411868251
- Cited by
- 59
- References
- 33
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 8 · 2020: 7 · 2019: 11 · 2018: 8 · 2017: 9 · 2016: 1
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Oncology Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Geriatrics and Gerontology › Frailty in Older Adults
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- immune checkpoint inhibitors, older adults, geriatric oncology, non-small cell lung cancer, melanoma, renal cell carcinoma, treatment toxicity, treatment efficacy, age-stratified outcomes, advanced cancer
- MeSH terms
- Age Factors, Aged, Antineoplastic Agents, Health Services for the Aged, Humans, Immunotherapy, Medical Oncology, Middle Aged, Neoplasms, Outcome Assessment, Health Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
